Summit Ivonescimab: 24% OS Reduction, Nov PDUFA

Summit Therapeutics (SMMT) released updated overall survival data from the Phase 3 HARMONi trial on July 22, 2026, showing ivonescimab plus chemotherapy cut the risk of death by 24% in Western patients with EGFR-mutant non-small cell lung cancer. The FDA is scheduled to decide on approval by November 14, 2026.

The numbers

The updated analysis showed an overall survival hazard ratio of 0.76 in Western patients, meaning a 24% reduction in the risk of death compared to chemotherapy alone. Median overall survival was 16.8 months for the ivonescimab arm versus 14.0 months for chemotherapy alone.

The Western patient results are consistent with the Asian patient population in the global Phase 3 study, which enrolled 438 patients total. The hazard ratio also matches the entire trial group, Summit noted.

This data matters because it addresses a key regulatory question: whether a drug originated in China works in non-Asian populations. Ivonescimab is a PD-1/VEGF bispecific antibody partnered from Akeso, a Chinese biotech. A bispecific antibody targets two different proteins simultaneously. In this case, it blocks PD-1 (to unleash immune response against the tumor) and VEGF (to cut off the tumor’s blood supply) with a single molecule.

The FDA accepted Summit’s biologics license application in January 2026 with a PDUFA date of November 14. A PDUFA date is the FDA’s statutory deadline to complete its review of a drug application.

The binary risk

Summit is a single-catalyst biotech. The company’s $11.4 billion market cap rests almost entirely on ivonescimab’s approval. If the FDA approves the drug, it would be the first PD-1/VEGF bispecific to reach the U.S. market for EGFR-mutant NSCLC patients who have exhausted tyrosine kinase inhibitor therapy.

The risk is real. HARMONi missed its primary overall survival endpoint in the initial analysis. The FDA had explicitly requested statistically significant OS data to support a filing, and Summit submitted anyway, framing the miss as a technical failure rather than a drug efficacy problem. This updated analysis strengthens the case but does not change the fact that the original primary endpoint was not met.

Summit also reported Q2 earnings with a net loss of $0.28 per share, in line with estimates, and announced a clinical trial collaboration with Arcus Biosciences (RCUS) to evaluate casdatifan combinations. The Arcus deal adds optionality beyond ivonescimab.

SMMT closed at $14.98 on July 22.

What to watch next

The November 14 PDUFA date is the binary event. If the FDA requests an advisory committee meeting before then, that signals regulatory uncertainty. No adcom request so far is a positive sign, but given the missed primary endpoint, an advisory committee remains possible.

For more on how FDA approval decisions work, see our coverage of GSK’s Jideytro approval.

Source: Summit Therapeutics press release | Fierce Pharma

What It Means for the Trade

The updated OS hazard ratio of 0.76 is the single most important number for the November 14 PDUFA, because the original HARMONi analysis missed its primary overall survival endpoint — the explicit thing the FDA told Summit it wanted to see. A 24% death-risk reduction with Western-patient consistency across the 438-patient global study is the strongest post-hoc rescue of a missed primary a filing can carry. It is still a post-hoc rescue. The market is holding an $11.4 billion market cap on a single molecule facing a regulator that has been given statistical grounds to refuse. That is the trade in one sentence.

The consistency argument matters: the Western hazard ratio matching both the Asian population and the full trial group addresses the “does a China-originated drug work in Western patients” question that has shadowed every China-partnered oncology asset. But cross-population consistency within one trial is not the same as meeting the pre-specified endpoint. An approval would be the first PD-1/VEGF bispecific in the U.S. market for post-TKI EGFR-mutant NSCLC, a population with no great options after osimertinib — that is the prize, and it justifies the market’s willingness to hold the position.

What to Watch Between Now and November 14

No adcom request so far is genuinely good news — advisory committees get convened when regulators have questions worth debating publicly, and a missed primary endpoint is exactly the kind of question that qualifies. If the FDA stays silent through October, the approval probability improves materially. If an adcom appears, expect the stock to reprice fast, because adcom on this filing means the missed-endpoint issue is alive.

The Arcus casdatifan collaboration is small optionality and should not be part of the sizing decision. The Q2 loss of $0.28 per share is a rounding error against the binary. Position sizing here is the whole game: this is a single-catalyst company with a 100-day fuse, not a portfolio holding.

Risks and What Could Go Wrong

1. CRL on statistical grounds. The FDA declining to accept updated analyses in place of a missed primary is a well-established refusal pattern. Base rate for approvals after a missed primary endpoint: poor, even with supportive updates.
2. Narrow label. Even an approval may restrict use to populations or require confirmatory trials, capping near-term commercial value.
3. Competitive encroachment. Amivantamab-based regimens are expanding in EGFR-mutant NSCLC; every quarter of delay in Summit’s launch window is a quarter the post-TKI standard moves without them. Size for the binary and respect the base rate.